AFP and hypertensive disorder: In addition, the cost-effectiveness analysis results were robust in the scenario analyses, which included: the ITT population from the REFLECT trial, an extrapolation without the AFP covariate stratification, shortening the model time horizon, doubling the discount rates, lowering AE treatment costs, larger hypertension disutility, and dose intensity and distribution aligned with Japanese population characteristics.